.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Early technology review (ETR) serves as a critical strategic tool for health technology developers today. By engaging multiple stakeholders during the initial prototype phase, companies can align their products with the specific needs of payers and clinical experts. This proactive approach ensures that medical innovations are not only technically feasible but also commercially and clinically viable. Consequently, this method is especially relevant in rapidly growing healthcare markets like India.
The ETR process provides a structured framework for evaluating outcomes at the proof-of-concept stage. For instance, generic case studies highlight how expert advice can significantly alter a technology's strategic direction. In one successful case, a company followed the advice and expedited its first-in-human study. Furthermore, the iterative nature of this review allows for continuous refinement. Moreover, developers can identify potential barriers to adoption early on. Because of this, they avoid facing costly setbacks after large-scale investments.
Additionally, adopting a sequential iterative approach across the entire technology life cycle reduces financial risk. Instead of relying on a single-stage assessment, this adaptive design allows for evidentiary development at multiple points. Researchers suggest that a lack of early engagement often leads to incomplete preparedness for clinical trials. Therefore, clinicians and innovators must advocate for early technology review to streamline the path from laboratory to bedside.
The primary goal is to align new health technologies with clinical and payer expectations during the prototype stage to reduce development costs and research waste.
A sequential approach allows for iterative feedback and adaptive design. Consequently, it minimizes financial risks and allows for more efficient evidence development throughout the product life cycle.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional consultation. Refer to the latest local and national guidelines for clinical practice.
References
Levin L et al. Early technology review during prototype development and at proof of concept: the case for developing a sequential versus a single-stage approach to early evidence development for health technologies. Int J Technol Assess Health Care. 2026 Apr 22. doi: 10.1017/S0266462326103596. PMID: 42017345.
Grutters JPC et al. Defining early health technology assessment: building consensus using Delphi technique. Int J Technol Assess Health Care. 2025;41(1):e1. doi: 10.1017/S026646232500001X.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Early technology review (ETR) helps health tech developers reduce costs and risks by engaging stakeholders during the prototype and proof-of-concept stages....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
